文献速递造血干细胞移植与细胞治疗

托珠单抗对比安慰剂联合环孢素/甲氨蝶呤预防GVHD的3期双盲研究

A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis.
PubMed 文献 · Blood · 2021-01-01

在145例接受MSD或VUD异基因造血干细胞移植的急性白血病或骨髓增生异常患者中,随机加用托珠单抗或安慰剂至环孢素/甲氨蝶呤GVHD预防方案。

要点

  • 托珠单抗未显著降低2-4级aGVHD发生率,主要减少2级aGVHD。
  • 托珠单抗组中性粒细胞和血小板植入延迟2-3天。
  • 两组移植相关死亡、总生存、肝毒性和感染并发症无显著差异。

核心结论

  • 托珠单抗联合环孢素/甲氨蝶呤在HLA相合VUD移植中显示降低2-4级aGVHD的非显著趋势,但未改善长期生存。

研究设计与样本

  • 3期随机双盲试验,在5个澳大利亚中心纳入145例(50例MSD,95例VUD)接受清髓或减低强度预处理异基因造血干细胞移植的急性白血病或骨髓增生异常患者。
  • 患者随机分配至安慰剂组或托珠单抗组(第-1天给药),所有患者接受T细胞充足的外周血干细胞移植物及环孢素/甲氨蝶呤GVHD预防。
  • 预设亚组分析VUD队列。

临床怎么用

  • 托珠单抗联合环孢素/甲氨蝶呤未能显著降低2-4级aGVHD发生率,且不改善长期生存,暂不支持常规用于GVHD预防。
  • 使用托珠单抗需注意中性粒细胞和血小板植入延迟2-3天。
  • 对HLA相合VUD移植患者,托珠单抗降低aGVHD的趋势主要限于2级疾病,需权衡利弊。

局限性

  • 研究仅纳入5个澳大利亚中心,样本量145例,可能影响统计效力。
  • 主要终点未达到统计学显著性,结果仅为非显著趋势。
  • 预设亚组分析VUD队列,但未报告其他亚组结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We determined the efficacy of tocilizumab (TCZ) in preventing grade 2-4 acute graft-versus-host disease (aGVHD) in patients with acute leukemia or myelodysplasia undergoing matched sibling donor (MSD) or volunteer unrelated donor (VUD) allogeneic stem cell transplantation after myeloablative or reduced-intensity conditioning across 5 Australian centers. A total of 145 patients (50 MSD, 95 VUD) were randomly assigned to placebo or TCZ on day -1. All patients received T-cell-replete peripheral blood stem cell grafts and graft-versus-host disease (GVHD) prophylaxis with cyclosporin/methotrexate. A planned substudy analyzed the VUD cohort. With a median follow-up of 746 days, the incidence of grade 2-4 aGVHD at day 100 for the entire cohort was 36% for placebo vs 27% for TCZ (hazard ratio [HR], 0.69; 95% confidence interval [CI], 0.38-1.26; P = .23) and 45% vs 32% (HR, 0.61; 95% CI, 0.31-1.22; P = .16) for the VUD subgroup. The incidence of grade 2-4 aGVHD at day 180 for the entire cohort was 40% for placebo vs 29% for TCZ (HR, 0.68; 95% CI, 0.38-1.22; P = .19) and 48% vs 32% (HR, 0.59; 95% CI, 0.30-1.16; P = .13) for the VUD subgroup. Reductions in aGVHD were predominantly in grade 2 disease. For the entire cohort, transplant-related mortality occurred in 8% vs 11% of placebo-treated vs TCZ-treated patients, respectively (P = .56), and overall survival was 79% vs 71% (P = .27). Median day to neutrophil and platelet engraftment was delayed by 2 to 3 days in TCZ-treated patients, whereas liver toxicity and infectious complications were similar between groups. In this phase 3 randomized double-blind trial, TCZ showed nonsignificant trends toward reduced incidence of grade 2-4 aGVHD in recipients from HLA-matched VUDs but no improvements in long term-survival.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Kennedy GA, Tey SK, Buizen L, et al. A phase 3 double-blind study of the addition of tocilizumab vs placebo to cyclosporin/methotrexate GVHD prophylaxis. Blood. 2021. PMID: 33512442. doi:10.1182/blood.2020009050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。